The antitumor effects of sunitinib (formerly SU11248) against a variety of human hematologic malignancies: enhancement of growth inhibition via inhibition of mammalian target of rapamycin signaling. [electronic resource]
Producer: 20070130Description: 2522-30 p. digitalISSN:- 1535-7163
- Adaptor Proteins, Signal Transducing -- antagonists & inhibitors
- Antineoplastic Agents -- pharmacology
- Apoptosis
- Cell Cycle Proteins
- Cell Line, Tumor
- Cell Proliferation -- drug effects
- Drug Synergism
- Everolimus
- Hematologic Neoplasms -- enzymology
- Humans
- Indoles -- pharmacology
- Leukemia -- metabolism
- Mutation
- Phosphoproteins -- antagonists & inhibitors
- Protein Kinases -- physiology
- Pyrroles -- pharmacology
- Receptor Protein-Tyrosine Kinases -- genetics
- Ribosomal Protein S6 Kinases, 70-kDa -- antagonists & inhibitors
- Signal Transduction
- Sirolimus -- analogs & derivatives
- Sunitinib
- TOR Serine-Threonine Kinases
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.